{"id":"ac-170-0-1","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AC-170 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating diabetes.","oneSentence":"AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:35.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07461727","phase":"PHASE1","title":"An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-10","conditions":"Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases","enrollment":15},{"nctId":"NCT05922358","phase":"PHASE2","title":"Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-09-01","conditions":"Gastrointestinal Tumors","enrollment":500},{"nctId":"NCT05803070","phase":"","title":"Topical Cetirizine in Treatment of Localized Alopecia Areata","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-09-01","conditions":"Alopecia Areata","enrollment":59},{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT01134328","phase":"PHASE2","title":"Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2010-05","conditions":"Allergic Conjunctivitis","enrollment":83},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101},{"nctId":"NCT01902836","phase":"PHASE2","title":"Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2011-08","conditions":"Childhood Atopic Dermatitis","enrollment":58},{"nctId":"NCT00639587","phase":"PHASE3","title":"Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-08","conditions":"Rhinitis, Allergic, Perennial","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AC-170 0.1%","genericName":"AC-170 0.1%","companyName":"Aciex Therapeutics, Inc.","companyId":"aciex-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}